Thirty years of recombinant BCG: new trends for a centenary vaccine

Full metadata record
DC FieldValueLanguage
dc.contributorLab. de Desenvolvimento de Vacinaspt_BR
dc.contributor.authorMarques-Neto, Lazaro M.pt_BR
dc.contributor.authorPiwowarska, Zuzannapt_BR
dc.contributor.authorKanno, Alex Issamupt_BR
dc.contributor.authorMoraes, Luanapt_BR
dc.contributor.authorTrentini, Monalisa M.pt_BR
dc.contributor.authorRodríguez, Duniapt_BR
dc.contributor.authorSilva, Jose L. S. C.pt_BR
dc.contributor.authorLeite, Luciana Cezar de Cerqueirapt_BR
dc.identifier.citationMarques-Neto LM., Piwowarska Z, Kanno AI, Moraes L, Trentini MM., Rodríguez D, et al. Thirty years of recombinant BCG: new trends for a centenary vaccine. Expert Rev. Vaccines. 2021 Jul;20(8):1001-1011. doi:10.1080/14760584.2021.1951243.pt_BR
dc.description.abstractIntroduction: Global perception of the potential for Bacille Calmette-Guérin (BCG), and consequently recombinant BCG (rBCG), in a variety of prophylactic and therapeutic applications has been increasing. A century of information on BCG, and three decades of experience with rBCG, has generated solid knowledge in this field. Area covered: Here, we review the current state of knowledge of BCG and rBCG development. Molecular tools have facilitated the expression of a variety of molecules in BCG, with the aim of improving its efficacy as a tuberculosis vaccine, generating polyvalent vaccines against other pathogens, including viruses, bacteria, and parasites, and developing immunotherapy approaches against noninvasive bladder cancer. BCG’s recently appraised heterologous effects and prospects for expanding its application to other diseases are also addressed. Expert opinion: There are high expectations for new tuberculosis vaccines currently undergoing advanced clinical trials, which could change the prospects of the field. Systems biology could reveal effective biomarkers of protection, which would greatly support vaccine development. The development of appropriate large-scale production processes would further support implementation of new vaccines and rBCG products. The next few years should consolidate the broader applications of BCG and produce insights into improvements using the recombinant BCG technology.pt_BR
dc.relation.ispartofExpert Review of Vaccinespt_BR
dc.rightsOpen accesspt_BR
dc.titleThirty years of recombinant BCG: new trends for a centenary vaccinept_BR
dc.rights.licenseCC BYpt_BR
dc.contributor.external(UCBL1) Université Claude Bernard Lyon Ipt_BR
dc.contributor.external(USP) Universidade de São Paulopt_BR
dc.subject.keywordBCG vaccinept_BR
dc.subject.keywordpolyvalent vaccinespt_BR
dc.subject.keywordrecombinant BCGpt_BR
dc.relation.ispartofabbreviatedExpert Rev. Vaccinespt_BR
dc.identifier.citationabntv. 20, n. 8, p. 1001-1011pt_BR
dc.identifier.citationvancouver2021 Jul;20(8):1001-1011pt_BR
dc.contributor.butantanKanno, Alex Issamu|:Pesquisador|:Lab. de Desenvolvimento de Vacinaspt_BR
dc.contributor.butantanRodríguez, Dunia|:Pesquisador|:Lab. de Desenvolvimento de Vacinaspt_BR
dc.contributor.butantanLeite, Luciana Cezar de Cerqueira|:Pesquisador|:Lab. de Desenvolvimento de Vacinaspt_BR
item.fulltextSem Texto completo-
Appears in Collections:Artigos de periódicos

Show simple item record

This item is licensed under a Creative Commons License Creative Commons